美国制药巨头礼来(LLY)今日盘前股价大涨7.63%,主要受益于其重磅减肥药Zepbound的供应短缺问题已经得到缓解。
美国食品和药物管理局(FDA)周四表示,礼来减肥药Zepbound的主要活性成分已不再短缺,这意味着FDA将禁止复方药房继续生产更便宜的仿制替西帕肽注射剂。FDA要求复方药房在未来60至90天内必须停止生产该仿制药。
自去年以来,Zepbound在美国和全球范围内供不应求,导致部分患者转而使用更实惠的复方药代替品。但礼来等制药商一直质疑复方药的质量和安全性。现在FDA已确认品牌药短缺状况结束,必将加强礼来的垄断地位,提振市场对其销售和盈利前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.